Investment
Features
FeesSafety
Academy
More
Pluang+

Genel Energy sees a 24.53% stake held by a concert party amid takeover designation.

Market News
13 Aug 2026
Proactive Investors
View Source
Neutral
pluang ai news

Genel Energy PLC has disclosed that a connected shareholder group now controls nearly a quarter (24.53%) of the company following its designation as a takeover target. Umit Tolga Bilgin is the largest individual in this concert party, holding 68.5 million shares mostly through Bilgin Enerji Yatirim Holding. Other related parties hold smaller stakes, and no special agreements exist between them. This disclosure is part of mandatory UK Takeover Code filings, signaling potential changes ahead for Genel Energy's ownership structure.

More News

Genasys Q3 revenue dips but gross margin jumps; analyst sees 108% stock gain potential

Genasys Q3 revenue dips but gross margin jumps; analyst sees 108% stock gain potential

Genasys reported a Q3 2026 revenue drop to $7.3M due to supply-chain issues and a work suspension, not demand loss. Despite this, gross margin improved to 57.1% and operating loss narrowed to $4M, showing better efficiency. An analyst raised the pric...

Company Fundamentals
Bullish
42 minutes ago
Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.

Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.

Definitive Healthcare Corp. stands out with a remarkable Return on Invested Capital (ROIC) of 41.44%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.78%. This means the company generates over seven times the value for every ...

Market News
Bullish
48 minutes ago
OptimumBank's price target raised to $11 amid strong financial growth and profitability.

OptimumBank's price target raised to $11 amid strong financial growth and profitability.

Industrial Alliance Securities raised OptimumBank Holdings' price target from $7.00 to $11.00, signaling a 15.24% potential upside. The bank shows strong financial health with a 2.04% ROAA, 20.34% ROAE, and a 4.57% net interest margin. Its loans grew...

Analyst Insights
Bullish
1 hour ago
Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...

Analyst Insights
Bearish
2 hours ago
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App